Fig. 2.
Fig. 2. Purification of myotube-synthesized hF.IX . / (A) 7.5% SDS-PAGE of purified human F.IX. Lane 1, myotube-synthesized hF.IX. Lane 2, HepG2 cell-synthesized F.IX. Lane 3, plasma-derived hF.IX. (B) Western blot of the same gel using a monoclonal antibody to the heavy chain of hF.IX. Lane 1, myotube-synthesized hF.IX. Lane 2, HepG2 cell-synthesized hF.IX. Lane 3, plasma-derived hF.IX (Mononine).

Purification of myotube-synthesized hF.IX .

(A) 7.5% SDS-PAGE of purified human F.IX. Lane 1, myotube-synthesized hF.IX. Lane 2, HepG2 cell-synthesized F.IX. Lane 3, plasma-derived hF.IX. (B) Western blot of the same gel using a monoclonal antibody to the heavy chain of hF.IX. Lane 1, myotube-synthesized hF.IX. Lane 2, HepG2 cell-synthesized hF.IX. Lane 3, plasma-derived hF.IX (Mononine).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal